REGN Regeneron Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: REGN

Price (delayed)

$514.80

Market cap

$54.93B

P/E Ratio

17.68

Dividend/share

N/A

EPS

$29.12

Enterprise value

$56.05B

Sector: Healthcare
Industry: Biotechnology
Website: https://www.regeneron.com/

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Tarrytown, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities , it ...

Highlights

The company's EPS rose by 48% YoY and by 7% QoQ
Regeneron Pharmaceuticals's net income has increased by 47% YoY and by 6% QoQ
The quick ratio has soared by 88% from the previous quarter but it has contracted by 3.8% YoY
The equity has grown by 12% since the previous quarter but it has declined by 3.6% year-on-year
The debt has increased by 22% from the previous quarter
The gross margin has contracted by 2.2% YoY

Key stats

What are the main financial stats of REGN
Market
Shares outstanding
106.71M
Market cap
$54.93B
Enterprise value
$56.05B
Valuations
Price to earnings (P/E)
17.68
Price to book (P/B)
5.41
Price to sales (P/S)
6.59
EV/EBIT
15.9
EV/EBITDA
14.94
EV/Sales
6.8
Earnings
Revenue
$8.24B
EBIT
$3.52B
EBITDA
$3.75B
Free cash flow
$1.58B
Per share
EPS
$29.12
Free cash flow per share
$15
Book value per share
$95.17
Revenue per share
$78.14
TBVPS
$152.45
Balance sheet
Total assets
$16.08B
Total liabilities
$5.96B
Debt
$2.69B
Equity
$10.13B
Working capital
$6.76B
Liquidity
Debt to equity
0.27
Current ratio
3.89
Quick ratio
3.02
Net debt/EBITDA
0.3
Margins
EBITDA margin
45.5%
Gross margin
88%
Net margin
38.3%
Operating margin
37.4%
Efficiency
Return on assets
20.7%
Return on equity
29.8%
Return on invested capital
28.3%
Return on capital employed
25.6%
Return on sales
42.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

REGN stock price

How has the Regeneron Pharmaceuticals stock price performed over time
Intraday
-5.39%
1 week
-5.07%
1 month
5.29%
1 year
51.67%
YTD
6.56%
QTD
6.56%

Financial performance

How have Regeneron Pharmaceuticals's revenue and profit performed over time
Revenue
$8.24B
Gross profit
$7.25B
Operating income
$3.09B
Net income
$3.16B
Gross margin
88%
Net margin
38.3%
Regeneron Pharmaceuticals's net income has increased by 47% YoY and by 6% QoQ
The operating income rose by 37% YoY and by 11% QoQ
The revenue has increased by 24% YoY and by 7% QoQ
Regeneron Pharmaceuticals's gross profit has increased by 22% YoY and by 7% from the previous quarter

Growth

What is Regeneron Pharmaceuticals's growth rate over time

Valuation

What is Regeneron Pharmaceuticals stock price valuation
P/E
17.68
P/B
5.41
P/S
6.59
EV/EBIT
15.9
EV/EBITDA
14.94
EV/Sales
6.8
The company's EPS rose by 48% YoY and by 7% QoQ
REGN's price to earnings (P/E) is 42% lower than its 5-year quarterly average of 30.3 and 17% lower than its last 4 quarters average of 21.2
REGN's price to book (P/B) is 17% less than its 5-year quarterly average of 6.5
The equity has grown by 12% since the previous quarter but it has declined by 3.6% year-on-year
The revenue has increased by 24% YoY and by 7% QoQ
The P/S is 8% lower than the 5-year quarterly average of 7.2 and 7% lower than the last 4 quarters average of 7.1

Efficiency

How efficient is Regeneron Pharmaceuticals business performance
Regeneron Pharmaceuticals's return on invested capital has increased by 34% YoY
Regeneron Pharmaceuticals's return on equity has increased by 34% YoY and by 7% QoQ
The company's return on sales rose by 26% YoY
The return on assets has increased by 25% year-on-year

Dividends

What is REGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for REGN.

Financial health

How did Regeneron Pharmaceuticals financials performed over time
REGN's total assets is 170% greater than its total liabilities
The quick ratio has soared by 88% from the previous quarter but it has contracted by 3.8% YoY
The current ratio has soared by 83% QoQ but it is down by 3.5% YoY
The debt is 73% less than the equity
The equity has grown by 12% since the previous quarter but it has declined by 3.6% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.